Showing results (1811-1820 of 1,873) with videos related to

Sort By:
Pageof 188
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Nature|October 29, 2020
Strategic vision for improving human health at The Forefront of GenomicsEric D Green, Chris Gunter, Leslie G Biesecker, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Cell|April 24, 2012
Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundariesMichael E Talkowski, Jill A Rosenfeld, Ian Blumenthal, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
European Heart Journal|March 25, 2015
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsDavid Preiss, Ross T Campbell, Heather M Murray, et al.
Journal of the American Heart Association|June 21, 2024
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic SubstudyNatasha L Patel-Murray, Luqing Zhang, Brian L Claggett, et al.
The New England Journal of Medicine|September 3, 2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionScott D Solomon, John J V McMurray, Inder S Anand, et al.
Pageof 188